PARIS - CARMAT’s Aeson artificial heart receives MDR CE marking

Published 28/07/2025, 17:06
PARIS - CARMAT’s Aeson artificial heart receives MDR CE marking

PARIS - CARMAT (Euronext Growth Paris:ALCAR), a €21.31M market cap medical device company, announced Monday it has obtained CE marking under the Medical Devices Regulation (MDR) for its Aeson artificial heart system, securing its regulatory status in European markets beyond May 2027. According to InvestingPro data, the company has achieved impressive revenue growth of 91.4% over the last twelve months.

The certification applies to the Aeson system as a Class III active implantable medical device for bridge-to-transplant (BTT) indication, meaning it can be used in patients awaiting heart transplantation.

This new certification replaces the previous Medical Device Directive (MDD) approval the device received in December 2020. Under European regulations, medical devices certified under the older MDD standard must transition to the more stringent MDR certification by May 2027 to remain marketable in the European Union.

The MDR certification was granted following a review conducted by notified body DEKRA and confirms the device’s compliance with updated European standards for patient safety, clinical performance, and risk management.

According to the company, Aeson is currently the only CE-marked implantable total artificial heart available in Europe.

Stéphane Piat, Chief Executive Officer of CARMAT, called the certification "a further independent recognition of Aeson’s quality and performance by health authorities."

The company noted the certification strengthens its foundation for potential future expansion of Aeson’s indications toward destination therapy, where the device would be implanted permanently without subsequent heart transplantation. It also supports CARMAT’s U.S. market access strategy, which is targeted for 2028.

Despite this regulatory milestone, CARMAT’s stock has declined 71.24% year-to-date, trading at €0.36. The company disclosed it has been in receivership procedure since July 1, 2025, and faces "a very high risk of default, including in the very short term," according to the press release statement. InvestingPro analysis reveals the company operates with significant debt burden and is quickly burning through cash reserves.

Want deeper insights? InvestingPro subscribers have access to 11 additional expert tips and comprehensive financial metrics for CARMAT.

The Aeson artificial heart is designed as an alternative to heart transplantation for patients with end-stage biventricular heart failure.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.